Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study
Authors:
- 25 August 2021
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 36 (6) , 1175-1186
Abstract
Introduction Recurrent event rates after myocardial infarction (MI) remain unacceptably high, in part because of the continued growth and destabilization of residual coronary atherosclerotic plaques, which may occur despite lipid-lowering therapy. Inflammation is an important contributor to this ongoing risk. Recent studies have shown that the broad-acting anti-inflammatory agent, colchicine, may reduce adverse cardiovascular events in patients post-MI, although the mechanistic basis for this remains unclear. Advances in endovascular arterial wall imaging have allowed detailed characterization of the burden and compositional phenotype of coronary plaque, along with its natural history and responsiveness to treatment. One such example has been the use of optical coherence tomography (OCT) to demonstrate the plaque-stabilizing effects of statins on both fibrous cap thickness and the size of lipid pools within plaque. Methods The Phase 2, multi-centre, double-blind colchicine for coronary plaque modification in acute coronary syndrome (COCOMO-ACS) study will evaluate the effect of colchicine 0.5 mg daily on coronary plaque features using serial OCT imaging in patients following MI. Recruitment for the trial has been completed with 64 participants with non-ST elevation MI randomized 1:1 to colchicine or placebo in addition to guideline recommended therapies, including high-intensity statins. The primary endpoint is the effect of colchicine on the minimal fibrous cap thickness of non-culprit plaque over an 18-month period. Summary The COCOMO-ACS study will determine whether addition of colchicine 0.5 mg daily to standard post-MI treatment has incremental benefits on high-risk features of coronary artery plaques. If confirmed, this will provide new mechanistic insights into how colchicine may confer clinical benefits in patients with atherosclerotic cardiovascular disease. Trial Registration ANZCTR trial registration number: ACTRN12618000809235. Date of trial registration: 11th of May 2018.Keywords
Funding Information
- National Health and Medical Research Council (ID 1127159, ID 1111630, CDF 1161506)
- National Heart Foundation of Australia (Vanguard Grant ID 10137, FLF 102535, FLF 102056)
- Sylvia and Charles Viertel Charitable Foundation (VIERCI 2017016)
This publication has 65 references indexed in Scilit:
- Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with GoutThe Journal of Rheumatology, 2012
- Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein LevelsCirculation, 2011
- NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?Nature Reviews Immunology, 2010
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2010
- Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart DiseaseJAMA, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Three-Dimensional Coronary Artery Microscopy by Intracoronary Optical Frequency Domain ImagingJACC: Cardiovascular Imaging, 2008
- Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.Journal of Clinical Investigation, 1995
- Elevation of C-reactive protein in “active” coronary artery diseaseThe American Journal of Cardiology, 1990
- Effects of methyl prednisolone and colchicine on the development of aortic atherosclerosis in swineAtherosclerosis, 1976